Epic Lawsuit, AI Funding & Health Tech News – March 26 2024

Good morning, health tech readers!

Spring has arrived, and with it, a flurry of activity in the health technology sector. Today, we’re looking at developments from STAT+, including a significant funding round for an AI-driven healthcare startup and a crucial update regarding Epic’s sepsis model. Plus, a closer look at Verily’s expanding services.

AI-Powered Healthcare Startup Secures Funding, Awaits FDA Review

A burgeoning AI-focused healthcare company has recently completed a funding round, signaling growing investor confidence in the potential of artificial intelligence to transform medical care. While specific details regarding the company’s name and the amount of funding raised are currently exclusive to STAT+ subscribers, the news indicates a significant step forward for the application of AI in diagnostics, and treatment. The startup is also preparing to engage with the Food and Drug Administration (FDA), a critical milestone for any new health technology seeking to enter the market. More details are available on STAT+.

This development comes amidst increasing interest in AI’s role in healthcare. From assisting with image analysis to predicting patient outcomes, AI algorithms are being explored for a wide range of applications. However, the path to widespread adoption is not without its challenges, including concerns about data privacy, algorithmic bias, and the need for rigorous validation through clinical trials and regulatory review.

Epic Revamps Sepsis Prediction Model Following Scrutiny

Epic, a leading provider of electronic health records, is actively revising its sepsis prediction model in response to concerns raised about its accuracy and reliability. Recent investigations, as reported by STAT, revealed high rates of false alarms and an inability to consistently predict sepsis onset. Sepsis, a life-threatening condition caused by the body’s overwhelming response to an infection, requires rapid diagnosis and treatment. An inaccurate prediction model can lead to unnecessary interventions or, conversely, delayed care for patients who truly need it.

The changes implemented by Epic include recommending that hospital customers train the model using their own data before deployment. This customization is intended to improve the model’s performance by accounting for the unique characteristics of each hospital’s patient population and clinical practices. Epic has also adjusted its definition of “sepsis onset” to align with more widely accepted standards. This shift aims to reduce ambiguity and improve the consistency of sepsis identification across different healthcare settings. STAT’s initial reporting on the sepsis model provides further context on these issues.

The evolution of Epic’s sepsis model highlights the complexities of implementing AI in clinical practice. While AI holds immense promise for improving healthcare, it’s crucial to acknowledge its limitations and continuously refine algorithms based on real-world data and feedback from clinicians. The need for ongoing monitoring and evaluation is paramount to ensure that these tools are truly benefiting patients.

Verily Expands Services with ‘Verily Me’ and Enhanced Chatbot Capabilities

Verily, an Alphabet company focused on precision health, has announced the general availability of “Verily Me,” a free service offering clinician review of personal health records. This service aims to empower individuals to better understand their health data and identify potential areas of concern. Complementing Verily Me is Violet, an AI-powered chatbot designed to answer user questions about their health records. A new feature allows Violet to engage in multi-turn conversations about symptoms, providing a more interactive and personalized experience. Learn more about Verily’s mission and services.

The launch of Verily Me and the enhanced capabilities of Violet reflect a growing trend towards patient-centered healthcare. By providing individuals with greater access to their health information and tools to interpret it, Verily is aiming to foster more informed decision-making and proactive health management. The chatbot’s ability to engage in conversational interactions could be particularly valuable for individuals who have difficulty navigating complex medical terminology or understanding their health records.

However, it’s important to remember that these tools are not substitutes for professional medical advice. Individuals should always consult with a qualified clinician for diagnosis and treatment of any health condition. The information provided by Verily Me and Violet should be considered supplementary to, not a replacement for, the expertise of a healthcare professional.

Understanding the Role of the FDA in AI-Driven Healthcare

The FDA plays a critical role in ensuring the safety and effectiveness of medical devices, including those powered by artificial intelligence. The regulatory pathway for AI-driven healthcare tools is evolving, as these technologies often present unique challenges compared to traditional medical devices. The FDA is actively working to develop a framework for evaluating and approving AI algorithms, taking into account factors such as data quality, algorithmic bias, and the potential for unintended consequences.

The agency’s approach to AI regulation is likely to be risk-based, with more stringent requirements for tools that pose a higher risk to patient safety. For example, an AI algorithm used to diagnose a life-threatening condition would likely be subject to more rigorous scrutiny than an algorithm used to provide personalized wellness recommendations. The FDA is also exploring the use of “real-world evidence” to monitor the performance of AI algorithms after they have been approved for use, allowing for continuous improvement and refinement.

The engagement between the recently funded AI startup and the FDA will be a closely watched case, potentially setting precedents for future regulatory approvals of similar technologies. The process will likely involve submitting detailed documentation on the algorithm’s design, training data, and performance characteristics, as well as demonstrating its clinical validity and safety.

What comes next for these developments? Continued monitoring of Epic’s sepsis model performance, particularly after hospital-specific training, will be crucial. The FDA’s review of the new AI startup’s technology will shape the future of AI-driven diagnostics. And Verily’s expansion of services will likely be followed by further innovation in patient-facing health technology. These are all areas to watch closely as the health tech landscape continues to evolve.